Pacira BioSciences Executive Kristen Williams Has Sold $14M in PCRX Stock — Annual Pattern Continues
Kristen Williams, a Pacira BioSciences executive, has sold $14M in PCRX stock over 141 transactions in a consistent annual selling pattern since 2019.
Kristen Williams, an executive at Pacira BioSciences (PCRX), has sold $14 million in company stock across 141 transactions in a remarkably consistent annual pattern.
The Numbers
| Metric | Value |
|---|---|
| Career Sell Value | $14.0M |
| Career Buy Value | $0 |
| Total Transactions | 141 |
| Last Transaction | 2026-02-02 |
| Shares Remaining | 131,303 |
Recent Activity
| Date | Type | Shares | Price | Est. Value |
|---|---|---|---|---|
| 2026-02-02 | Sell | 13,137 | $20.5300 | $270K |
| 2025-06-04 | Sell | 14,376 | $26.2400 | $377K |
| 2024-06-13 | Sell | 7,452 | $28.3800 | $211K |
| 2023-06-14 | Sell | 6,467 | $37.0300 | $239K |
| 2023-06-07 | Sell | 1,357 | $37.8650 | $51K |
Williams sold 13,137 shares at $20.53 on February 2, 2026, for approximately $270K. Her pattern shows annual selling clusters — June 2025 ($377K), June 2024 ($211K), June 2023 ($290K), June 2022 ($521K) — suggesting a recurring 10b5-1 plan execution window.
What It Means
Williams' selling follows a textbook 10b5-1 pattern: clustered disposals once or twice per year, typically around the same calendar months. The declining per-trade values — from $521K in 2022 to $270K in 2026 — mirror PCRX's share price erosion from $60+ to $20, not changes in her selling behavior.
For PCRX investors, Williams' 131,303 remaining shares represent meaningful continued exposure. Pacira's non-opioid pain management portfolio faces both opportunity and competition as the healthcare industry navigates post-opioid-crisis treatment paradigms. The consistent selling without acceleration at declining prices is modestly constructive.
What to Watch
- PCRX share price trajectory and pain management market share
- Whether Williams adjusts her selling plan at $20 price levels
- FDA updates on Pacira's Exparel and iovera portfolios
- Other PCRX insider activity for corroborating signals
Related Research
Explore all researchAmeriprise Financial's 11,224-position portfolio has the lowest top-5 concentration of any mega-filer at 14.8%. Netflix shares surged 943%, confirming an institutional consensus trade across $2.7 trillion in combined AUM. Salesforce built 82%.
Mar 6, 2026
Britain's largest asset manager holds NVIDIA at $32B and Apple at $30B in an unusually close #1/#2 race. AUM crashed $102B between Q3 and Q4 2024, then recovered. Netflix shares surged 916% — the fourth mega-filer to make this trade in Q4.
Mar 6, 2026
The second Capital Group division to file a massive Netflix build in Q4 2025. Capital Research Global also doubled its Applied Materials position, holds $26B in Eli Lilly, and opened a $1B position in MicroStrategy — the Bitcoin proxy.
Mar 6, 2026
Canada's largest bank filed a U.S. 13F with 29,036 positions, three S&P 500 ETFs in its top 5, $12.5B of its own stock (RY), and $11.9B of competitor Toronto-Dominion. Netflix shares surged 893% in one quarter.
Mar 6, 2026
While most mega-filers lead with NVIDIA, Capital International Investors bets biggest on Broadcom at 7.7% of portfolio. They also increased Netflix shares by 710% in Q4 2025, added $3.4B in TotalEnergies, and exited Disney entirely.
Mar 6, 2026